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BACKGROUND: In colorectal cancer (CRC), DNA methylation anomalies define distinct subgroups termed CpG island
methylator phenotype 1 (CIMP1), CIMP2, and CIMP-negative. The role of this classification in predicting recurrence
and disease-free survival (DFS) in resected stage III CRC was evaluated. METHODS: Sporadic cancers from 161
patients were analyzed. Bisulfite pyrosequencing was used to examine the methylation of 2 global DNA methylation
markers (LINE-1, Alu) and 9 loci (MINT1, MINT2, MINT31, P16, hMLH1, P14, SFRP1, SFRP2, and WNT5A). Mutations in
BRAF and KRAS were assayed. RESULTS: Gene hypermethylation clustered in discrete groups of patients, indicating
the presence of CIMP. K-means clustering analysis identified 3 discrete subgroups: CIMP1 (n ¼ 22, 13.7%), associated
with proximal location and BRAF mutations; CIMP2 (n ¼ 40, 24.8%), associated with KRAS mutations; and CIMP-neg-
ative (n ¼ 99, 61.5%), associated with distal location. In proximal CRC, CIMP1 was correlated with a higher recurrence
rate (53% for CIMP1, 18% for CIMP2, and 26% for CIMP-negative) and a worse DFS (P ¼ .015). Also in proximal CRC,
LINE-1 methylation was lower in patients whose cancer recurred compared with those whose cancer did not recur
(P ¼ .049). In multivariate analysis, CIMP1 and low LINE1 methylation were independent prognostic factors for DFS in
proximal CRC (P ¼ .008 for classification by K-means clustering analysis; P ¼ .040 for LINE-1 methylation status).
CONCLUSIONS: DNA methylation is a useful biomarker of recurrence in resected stage III proximal but not distal
CRC. However, as the number of CIMP1 cases was small in distal CRC, further study is required to validate our
findings. Cancer 2011;117:1847–54. VC 2010 American Cancer Society.
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Cancer develops under the influence of genetic and epigenetic alternations.1,2 DNAmethylation is a main component
of epigenetics, and the relationship between DNA methylation and carcinogenesis has been extensively studied in various
cancers.1,3 In cancer, DNA methylation has 2 main patterns. Cancer cells have decreased global methylation compared
with normal cells,4,5 which may be involved in genetic instability.6-8 LINE-1 methylation density is a good indicator of
global methylation.9 Decreased LINE-1 methylation was associated with decreased survival in colorectal cancer.10 In con-
trast, there is increased CpG Island methylation density in the promoter regions of tumor-suppressor genes.1,3 This hyper-
methylation causes decreased gene expression and is involved in carcinogenesis through silencing tumor-suppressor genes.
DNAmethylation has been extensively studied in colon cancer.3,11 Colon cancer can be divided into subsets accord-
ing to DNA methylation patterns: CpG Island methylator phenotype–positive (CIMPþ) and CIMP groups. CIMPþ
cancers show distinct clinicopathologic features including female preponderance, older age, proximal colon location, and
mucinous and poorly differentiated histology.11 They are associated with microsatellite instability (MSI) and BRAFmuta-
tions.12 Although, CIMPþ cancers share many clinical features with MSI-related cancers, their prognosis is different.
CIMPþ cancers are associated with poor prognosis,13,14 whereas MSI-related cancers have a good prognosis.15,16 Multi-
ple genes may be responsible for the prognostic effects of DNA methylation in colorectal cancer (CRC), includingWNT
pathway genes. Abnormal activation of theWNT/beta catenin pathway is frequently found in gastrointestinal cancers17,18
and colon carcinogenesis.17,19,20 One of the important mechanisms of WNT pathway activation is the decreased produc-
tion of gene products that have an inhibitory effect on the WNT pathway. SFRP, DKK, andWNT5A are recognized to be
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WNT pathway antagonists.21 The promoter region of
WNT5A is frequently methylated in colon cancer tissue,
and preservedWNT5A expression was reported to be asso-
ciated with a good prognosis in colon cancer,22 whereas
promoter methylation of WNT pathway antagonists was
associated with a poor prognosis.23,24
There are embryologic, histologic, physiologic, and
biochemical differences between proximal colon and dis-
tal colons.25,26 Proximal colon consists of the cecum,
ascending colon, and proximal two-thirds of the trans-
verse colon. It develops from the embryonic midgut,
whereas the distal colon develops from the embryonic
hindgut. There is a difference in gene expression between
the proximal and distal colons. More than 1000 genes
were found to be differentially expressed in the adult
colon but only 87 genes differentially expressed in the fetal
stage.27 Around 70% of these genes were found to be
highly expressed in the distal colon. Based on these results,
it is reasonable to consider the proximal and distal colons
to be physiologically distinct, and the cancers that arise
from them could also be quite different.
In this study, we evaluated the potential role of
DNA promoter methylation biomarkers, genetic bio-
markers (KRAS and BRAF mutations) and global DNA
methylation biomarkers to predict recurrence and disease-
free survival (DFS) according to cancer location in cura-
tively resected stage III colon cancer.
MATERIALS AND METHODS
Tissue Samples
We used 161 stage III colon adenocarcinoma specimens
obtained at the time of curative resection at the Yonsei
Cancer Center, Severance Hospital (Seoul, Korea) from
1997 to 2006. The specimens were immediately frozen in
liquid nitrogen and stored at 80C. We excluded cases
of hereditary colon cancer. The collection of samples was
approved by the Severance Institutional Review Board,
and informed consent was obtained from patients to use
their surgical specimens and clinicopathologic data for
research purposes.
Assay of DNA Methylation
Bisulfite-treated genomic DNA was used to evaluate the
methylation status of 2 global methylation markers
(LINE-1, Alu) and the methylation status of 9 CpG
islands (MINT1, MINT2, MINT31, hMLH1, p16, p14,
SFRP1, SFRP2, and WNT5A). Bisulfite treatment of
DNA was performed with an EpiTect bisulfite kit (Qia-
gen, Valencia, CA) according to the manufacturer’s pro-
tocol. One microliter of bisulfite-treated DNA was used
as a template in subsequent polymerase chain reaction
(PCR). All PCR assays included a denaturation step at
95C for 30 seconds, followed by an annealing step at var-
ious temperatures for 30 seconds, and an extension step at
72C for 30 seconds. After PCR, the biotinylated strand
was captured on streptavidin-coated beads (Amersham
Bioscience, Uppsala, Sweden) and incubated with
sequencing primers. Pyrosequencing was performed with
PSQ HS 96 Gold single-nucleotide polymorphism
reagents on a PS QHS 96 pyrosequencing machine (Biot-
age, Uppsala, Sweden). The protocol for pyrosequencing
was described in detail previously.28 Pyrosequencing
quantitatively measures the methylation status of several
CpG sites in a given sequence. Therefore, we could deter-
mine the mean percentage of methylation of detected sites
as a representative value.
Assay of BRAF and KRAS Mutations
Genomic DNA was used to study the mutation status
of BRAF and KRAS genes. Mutation status was
determined with pyrosequencing assays. Mutations of
BRAF codon 600 and KRAS codons 12 and 13 were deter-
mined by a pyrosequencing machine (Biotage, Uppsala,
Sweden).29,30
Data Analysis and Statistics
Pyrosequencing presents methylation and mutation levels
as a continuous value. The methylation status of CpG
Island markers was analyzed as either a continuous or cate-
gorical variable (negative, methylation level <15%; posi-
tive, methylation level 15%). The methylation status of
global methylation markers was analyzed as either contin-
uous or categorical variables (divided into 2 groups by
the median value). Mutation status was analyzed as a cate-
gorical variable (wild-type status, mutation level <15%;
mutation, mutation level 15%). All clinicopathologic
variables except age were used as categorical variables. Dif-
ferences in continuous variables between 2 groups were
evaluated by the Student t test, and differences in categori-
cal variables were evaluated by the chi-square test.
Correlation of methylation level between methylation
biomarkers was analyzed by calculating Spearman’s non-
parametric correlation coefficients (r and P). K-means
clustering on the basis of both genetic and epigenetic
profiling was performed to identify potential discrete sub-
groups among colon cancer patients. K-means clustering
analysis was conducted using ArrayTrack version 3.4.0
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(NCTR/FDA, Jefferson, Ark). DFS was measured from
the date of resection of colon cancer to the date of event or
the last follow-up date before December 31, 2008. Event
was defined as recurrence, death due to any cause, or de-
velopment of a second primary in colorectal cancer. Me-
dian follow-up duration was 46 months. The Kaplan-
Meier method was used to calculate and display disease-
free survival curves, and the log-rank test was performed
to determine differences among all groups. The Cox
proportional hazards regression method was used to
determine independent prognostic factors.
All P values were 2 sided, and a P< .05 was consid-
ered statistically significant.
RESULTS
Clinicopathologic Characteristics
We studied 161 patients selected based on sample avail-
ability. Mean age was 61 years (range, 31-84 years), 93
patients were male (58%), and 76 tumors (47%) were in
the proximal colon. All patients were treated with post-
operative adjuvant chemotherapy consisting of 5-fluo-
rouracil and leucovorin. Among the 156 patients with
adequate follow-up data, there were 48 recurrences
(31%), 23 in the proximal colon and 25 in the distal
colon. The clinicopathologic features of the patients
analyzed by tumor location are summarized in Table 1.
Overall, there were no differences in sex, age, histology,
differentiation, T stage, N stage, or recurrence rate
between those with proximal colon cancer and those with
distal colon cancer.
Mutations of BRAF, KRAS, and Microsatellites
The mutation status of BRAF at codon 600 and of KRAS
at codon 12,13 was determined by pyrosequencing. There
were 7 cases (4.3%) with BRAF mutation, all in the
proximal colon. As for KRAS, 56 cases (34.8%) showed
mutations, and these were not associated with age, sex,
tumor location, or histology. There was no case harboring
both KRAS and BRAF mutations. Microsatellite instabil-
ity (MSI) status was previously determined, and data were
available on 91 patients. Of these, 17 (18.7%) showed
MSI, which was associated with proximal location.
Gene-Specific Methylation Analysis
The methylation frequencies of the 9 genes analyzed were
17% for MINT1, 22% for MINT2, 19% for MINT31,
16% for P16, 6% for MLH1, 9% for P14, 54% for
WNT5A, 93% for SFRP2, and 99% for SFRP1. Methyla-
tion of all the genes showed significant positive correla-
tions with each other (not shown), consistent with the
presence of CIMP in a subset of cases. Seven genes (all
except SFRP1 and SFRP2) showed strong correlations and
appeared to be excellent CIMP markers. For descriptive
purposes, we defined CIMP as positive when 3 or more of
the 7 markers were positive. Based on this definition, 29
cases (18%) were CIMPþ. As previously reported,11,12
CIMP was significantly associated with female sex, proxi-
mal colon cancer, BRAF mutation, and microsatellite
instability–high (MSI-H).
K-Means Clustering Based on Combined
Genetic and Epigenetic Information
We have previously reported that colon cancer falls into 3
distinct groups based on combined genetic and epigenetic
analysis.30 In the current data set, 3 distinct groups were
similarly identified by K-means clustering analysis of
the promoter methylation status of the 9 genes and the
mutation status of BRAF and KRAS (Fig. 1). The clinico-
pathologic and molecular features of the 3 groups are
Table 1. Clinicopathologic Characteristics According
to Tumor Location
Location
Proximal Distal P
Number 76 85
Age, y mean (range) 61.9 (31-84) 60 (31-82) .315
Sex
Male 44 49 .975
Female 32 36
Histology
Adeno 70 83 .106
Mucinous 6 2
Differentiation
WD 8 10 .824
MD 58 70
PD 4 3
T stage
1 1 2 .664
2 5 10
3 55 58
4 15 15
N stage
1 54 57 .585
2 22 28
Recurrence
No 52 56 .979
Yes 23 25
WD, well differentiated; MD, moderately differentiated; PD, poorly differenti-
ated; adeno, adenocarcinoma; mucinous, mucinous adenocarcinoma.
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summarized in Table 2. The CIMP1 (methylation-high)
group was characterized by a relatively high rate of BRAF
mutations and MSI-H, and most cases (82%) were in the
proximal colon. The CIMP2 group was characterized by a
high rate of KRAS mutation, whereas the CIMP-negative
group had rare mutations and low levels of methylation.
CIMP2 and CIMP-negative cases were slightly more
common among the distal cancers.
Given the reproducibility of the classification of
colon cancer into 3 groups, we evaluated recurrence rates
and DFS by this classification. Overall, CIMP1 cases had
the highest rate of recurrence (9 of 21, or 42.9%, com-
pared with 39 of 135, or 28.9%, in CIMP2 and CIMP-
negative), but this was not statistically significant. Because
of the strong site imbalance in the distribution of cases, we
evaluated DFS by site. There was a significant DFS differ-
ence among the 3 groups in proximal colon cancer
(Fig. 2a), showing the worst survival in CIMP1 (HR, 3.9;
95% CI, 1.08-14.35; P ¼ .015). This difference was not
observed in distal colon cancer (P¼ .304; Fig. 2b).
CIMP1 is associated with both MLH1 methylation
and BRAFmutation. Previous data suggested that MLH1
methylation is associated with good prognosis, whereas
BRAF mutation leads to a poor prognosis.31 To test this,
we subdivided CIMP1 into 3 groups (MLH1methylation
positive, n ¼ 7; MLH1 methylation negative and BRAF
mutation positive, n¼ 4; neither MLH1 methylation nor
BRAFmutation, n¼ 11) and evaluated DFS. Despite the
very small number of patients in each group, there was a
significant DFS difference between the 3 subgroups,
showing the best survival in MLH methylationþ patients
and the worst survival in MLH methylation and BRAF-
mutated patients (P¼ .016; Fig. 2c).
Global DNA Methylation Analysis
We evaluated global DNA methylation using LINE-1
and Alu methylation. High methylation of LINE-1 was
Figure 1. K-means clustering analysis based on genetic and epigenetic information is shown. Ninety-nine cases were classified as
group 1 (low methylation), 40 cases were classified as group 2 (intermediate methylation), and 22 cases were classified as group
3 (high methylation).
Table 2. Clinicopathologic Characteristics According to
Groups by K-Means Clustering Analysis
Group
1, Low
Methyl
2,
Intermediate
3, High
Methyl
P
Number 99 40 22
Age, y (mean) 60.8 59.3 64.3 .257
Sex
Male 60 22 11 .608
Female 39 18 11
Site
Proximal 42 16 18 .002a
Distal 57 24 4
Histology
Adeno 94 38 21 .995
Mucinous 5 2 1
Differentiation
WD 12 5 1 .646
MD 78 32 18
PD 4 1 2
T stage
1 3 0 0 .344
2 8 5 2
3 74 26 13
4 14 9 7
N stage
1 70 26 15 .802
2 29 14 7
Recurrence
No 67 29 12 .424
Yes 28 11 9
LINE1, meanSD 50.18.4 50.44.6 53.66.2 .14
MSI statusb
MSS or MSI-L 47 21 6 .034a
MSI-H 10 2 5
WD, well differentiated; MD, moderately differentiated; PD, poorly differenti-
ated; adeno, adenocarcinoma; mucinous, mucinous adenocarcinoma.
a Significant difference among groups by K-means clustering analysis.
b Available for a subset of patients only.
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significantly associated with CIMP1, high methylation of
Alu, low methylation of SFRP1, and low methylation of
SFRP2. No differences were noted in age, sex, tumor loca-
tion, histology, KRAS status, or MSI status according to
LINE-1 methylation status. In proximal colon cancer,
methylation level of LINE-1 was significantly lower in
patients with recurrent cancer than in patients with non-
recurrent cancer (48.5  8.6 vs 52.3  7.2, respectively;
P¼ .049; Fig. 3). No difference was found in distal colon
cancer. Lowmethylation of LINE-1 in the proximal colon
Figure 2. Kaplan-Meier survival estimates in colon cancer are shown. DFS in proximal colon cancer (a) and distal colon cancer
(b) according to groups classified by K-means clustering analysis using genetic and epigenetic information is shown. DFS in co-
lon cancer (c) according to groups classified by MLH methylation and BRAF mutation status in the high methylation group is
shown. DFS in proximal colon cancer (d) and distal colon cancer (e) according to groups classified by LINE-1 methylation is
shown.
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cancer was associated with a trend towards shorter DFS
(P ¼ .097). In distal colon cancer, there was no differ-
ence in DFS survival according to methylation status of
LINE-1 (Fig. 2d,e).
Multivariate Analysis of DFS
Table 3 shows multivariate analysis that included known
clinicopathologic characteristics associated with DFS (T
stage, N stage, tumor location, CEA) and other potential
molecular biomarkers (LINE-1 methylation status, BRAF
status, KRAS status, and grouping by K-means clustering
analysis of genetic and epigenetic information). LINE-1
methylation and grouping by K-means clustering analysis
were independent prognostic factors for DFS in proximal
colon cancer (P ¼ .040 for LINE-1 methylation status;
P¼ .008 for grouping by K-means clustering analysis). N
stage was the only independent prognostic factor in distal
colon cancer (P ¼ .004). In multivariate analysis using
classification based on epigenetic information alone
(CIMP) instead of using K-means clusters, BRAF status,
LINE-1 methylation status, and CIMP status were inde-
pendent prognostic factors for DFS in proximal colon
cancer (P ¼ .035 for BRAF status; P ¼ .007 for LINE-1
methylation status; P ¼ .011 for CIMP status) but not in
distal colon cancer.
DISCUSSION
In this study, we showed that methylation biomarkers
play a differential role in CRC recurrence and DFS by tu-
mor location. Using gene methylation and mutation, we
could cluster cases into 3 distinct groups. The high meth-
ylation group demonstrated a significant association with
CIMPþ, BRAF mutation, and MSI-H. The intermediate
methylation group showed a significant association with
high frequency of KRAS mutation. These molecular fea-
tures were almost the same as those that we previously
reported30 in a different population of patients, demon-
strating the reproducibility of this classification. Methyla-
tion-related biomarkers influenced recurrence and DFS in
resected stage III proximal colon cancer but not in distal
colon cancer. The study adds to the growing literature on
differences between proximal and distal cancers and sug-
gests that these may have to be taken into account in the
management of and clinical trials in this disease.
CIMP-negative colon cancers are evenly distributed
throughout the colon, but CIMP1 colon cancers are prin-
cipally located in the proximal colon.32 The cause of this
Figure 3. Methylation levels of LINE-1 according to recurrence
are shown. In proximal colon cancer, the methylation level of
LINE-1 was significantly lower in patients with recurrent can-
cer than in patients with nonrecurrent cancer (a), but not in
patients with distal cancer (b).
Table 3. Multivariate Cox Regression Model of
Prognostic Factors of DFS in Colon Cancer
Patients According to Location
HR 95% CI P
All colon
N stage .001
N1 1 1.48-4.43
N2 2.56
Proximal colon
LINE-1 methylation .040
High 1 1.04-5.64
Low 2.43
K-means clustering .008
Group 1 1.28 0.36-4.59
Group 2 1 1.22-16.25
Group 3 4.44
Distal colon
N stage .004
N1 1 1.43-6.35
N2 3.01
HR, hazard ratio; CI, confidence interval.
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difference is unknown. It may be that site-specific carcino-
gens, or differences in the cell of origin may explain this
variation in DNA methylation. Still, only about half of
proximal cancers are CIMP1, and our data now suggest
that DNA methylation may help in classification of these
patients for prognostic purposes. A high risk for recur-
rence of stage III CRCmay lead to more intensive surveil-
lance and novel adjuvant therapy strategies. We have
previously reported that the methylation status of several
CIMP markers was associated with poor survival in stage
IV CRC,14 but it is not yet known whether this is modu-
lated by site. One of the paradoxical findings on the effects
of CIMP on survival is the finding that CIMP1 is also
associated with MLH1 methylation, which results in
MSI. MSI is generally a favorable prognostic factor in
CRC.15,16 MSI was relatively rare in the population of
patients we studied, which explains why the dominant
effect of CIMP was negative on DFS. In a small pilot anal-
ysis, we did find that MLH1 methylated cases had a good
outcome, whereas CIMP1, MLH1 unmethylated cases
had a strikingly high recurrence rate, regardless of BRAF
mutation. It is interesting to consider why the 2 groups of
CIMP1 cases (MLH1 methylated/unmethylated) would
have such opposing consequences. An attractive hypothe-
sis is that the poor prognosis is imparted by DNA hyper-
methylation of genes such asWNT5A that results in more
aggressive behavior (increased invasion for example). In
turn, this invasive phenotype may be countered by induc-
tion of an immune response that is most pronounced in
MSI-positive cases.33
Here, we confirm a previous report on the prognos-
tic impact of LINE1 methylation on the outcome of
CRC10 but show that this is also limited to proximal
cancers. Others have examined the effect of global DNA
methylation on clinical outcomes in various cancers. In 1
study, the level of global DNA methylation was signifi-
cantly lower in prostate cancer than in normal prostate,
but there was no difference according to recurrence.34 In
ovarian cancer, the level of LINE-1 methylation was
significantly lower than that in normal tissue, and there was
a shortened survival in the low methylation group.35 The
mechanisms by which a low level of LINE-1 methylation is
associated with poor outcome remain to be determined.
Possibilities include association with genomic instability or
with activation of expression of selected genes.
It is interesting to consider why DNA methylation
was associated with recurrence in proximal cancers but
not in distal cancers. A simple possibility relates to the
rarity of CIMP1 cases in distal cancer, which limited our
power to detect a prognostic impact there. Larger studies
should address this issue. It is also possible that some other
molecular marker, not measured here, has a dominant
effect on recurrence and thus negates the effect of methyl-
ation differences on outcomes. Indeed, deletions of chro-
mosome 18 are associated with recurrences in stage III
CRC,36 and these are more common in distal cancers and
CIMP-negative cases.37,38 Thus, it may be that DNA
methylation is a dominant prognostic factor in proximal
cancers, whereas genetic instability is a dominant prog-
nostic factor in distal cancers. Our studies and these
hypotheses, which need to be confirmed in a larger popu-
lation, pave the way for individualized management of
stage III CRC.
In summary, methylation biomarkers such as methyl-
ation ofWNT5A, CIMPmarkers, and LINE-1 can predict
disease recurrence and DFS in resected stage III proximal
colon cancer but not in distal cancer. However, as the num-
ber of CIMP1 cases of distal CRC in our study was small,
further study is required to validate our findings. Classifica-
tion of CRC by both genetic and epigenetic profiles will
likely improve the capability of predicting prognosis and of
applying tailored therapy in this disease, but this classifica-
tion will also have to take into account differences between
proximal and distal cancers.
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